Alantolactone selectively ablates acute myeloid leukemia stem and progenitor cells by Ding, Yahui et al.
Alantolactone selectively
ablates acute myeloid leukemia
stem and progenitor cells
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Ding, Yahui, Huier Gao, Yu Zhang, Ye Li, Neil Vasdev, Yingdai Gao,
Yue Chen, and Quan Zhang. 2016. “Alantolactone selectively ablates
acute myeloid leukemia stem and progenitor cells.” Journal of
Hematology & Oncology 9 (1): 93. doi:10.1186/s13045-016-0327-5.
http://dx.doi.org/10.1186/s13045-016-0327-5.
Published Version doi:10.1186/s13045-016-0327-5
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:29407735
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
RESEARCH Open Access
Alantolactone selectively ablates acute
myeloid leukemia stem and progenitor
cells
Yahui Ding1, Huier Gao2, Yu Zhang2, Ye Li1, Neil Vasdev3,4, Yingdai Gao2†, Yue Chen1† and Quan Zhang1*†
Abstract
Background: The poor outcomes for patients diagnosed with acute myeloid leukemia (AML) are largely attributed
to leukemia stem cells (LSCs) which are difficult to eliminate with conventional therapy and responsible for relapse.
Thus, new therapeutic strategies which could selectively target LSCs in clinical leukemia treatment and avoid drug
resistance are urgently needed. However, only a few small molecules have been reported to show anti-LSCs activity.
Methods: The aim of the present study was to identify alantolactone as novel agent that can ablate acute myeloid
leukemia stem and progenitor cells from AML patient specimens and evaluate the anticancer activity of alantolactone
in vitro and in vivo.
Results: The present study is the first to demonstrate that alantolactone, a prominent eudesmane-type sesquiterpene
lactone, could specifically ablate LSCs from AML patient specimens. Furthermore, in comparison to the conventional
chemotherapy drug, cytosine arabinoside (Ara-C), alantolactone showed superior effects of leukemia cytotoxicity while
sparing normal hematopoietic cells. Alantolactone induced apoptosis with a dose-dependent manner by suppression
of NF-kB and its downstream target proteins. DMA-alantolactone, a water-soluble prodrug of alantolactone, could
suppress tumor growth in vivo.
Conclusions: Based on these results, we propose that alantolactone may represent a novel LSCs-targeted therapy and
eudesmane-type sesquiterpene lactones offer a new scaffold for drug discovery towards anti-LSCs agents.
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Background
Patients diagnosed with acute myeloid leukemia (AML)
have poor outcomes, with <50 % overall survival rates for
younger patients and a <1 year for older patients [1, 2].
Such patients are typically treated with chemotherapy and/
or hematopoietic stem cell (HSC) transplantation [3]. Ef-
fective strategies for AML remission and cure are greatly
needed for the treatments. Leukemia stem cells (LSCs) can
give rise to either daughter or differentiated cells and are at-
tributed for maintaining and perpetuating AML specifically
leukemia initiation, resistance to chemotherapy, prognosis
relapse, and deterioration [2]. Similar to HSCs, LSCs also
have the features of self-renewal, multi-potent differenti-
ation, and relative quiescence [4–6]. Many clinical chemo-
therapy drugs which target cell cycle have little potency to
eliminate the LSCs because of its quiescent status. More-
over, the P-glycoprotein that could pump chemotherapy
drugs out of cancer cells is overexpressed on the surface of
LSCs [7], which leads to drug resistance. LSCs in AML pa-
tients are associated with the low remission rate, short
disease-free and overall survival rate [8]. Abnormal regula-
tion of some signal pathways, such as p53, NF-kB, ROS,
Wnt/β-catenin, or Notch pathway, is considered to be crit-
ical to the pathogenesis of LSCs. The recovery of these sig-
nal pathways is used for elimination of LSCs [9–13].
Previous studies have revealed that the subpopulation with
the surface antigens CD34+CD38– can be regarded as LSCs
[14–16]. Targeting and eliminating LSCs has been proposed
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as a promising strategy for treatment of AML to decrease
the rate of relapse or drug resistance. However, small mole-
cules that can selectively target LSCs are rare and still at
early stages of development, for example, parthenolide
(PTL) [17], niclosamide [18], dimethyl-aminoparthenolide
(DMAPT) [19], fenretinide [20], 4-benzyl-2-methyl-1,2,4-
thiadiazolidine-3,5-dione (TDZD-8) [21], AR-42 [22], 4-
hydroxynonenal (HNE) [23], and micheliolide (MCL) [24].
Alantolactone, a naturally occurring eudesmane-type ses-
quiterpene lactone (SL), showed multi-function in several
human cancer cell lines in vitro, such as inhibitory effect on
cancer cell survival and regulating NF-kB signal pathway
[25–27]. The goal of the present work is to evaluate the ef-
fects and mechanisms of alantolactone on LSCs. The result
indicated that alantolactone exhibited high cytotoxicity
both in primary AML cells and multi-drug resistant cells.
Alantolactone inhibited cell proliferation and induced
apoptosis in a dose-dependent manner in vitro. Interest-
ingly, alantolactone significantly induced apoptosis of CD34
+CD38– cells in primary AML specimens isolated from
blood samples of AML patients and exhibited little cytotox-
icity against normal hematopoietic cells. Moreover, alanto-
lactone inhibited AML colony formation in vitro. In a
NOD/SCID mice xenograft assay, a water-soluble prodrug
DMA-alantolactone, was shown to suppress tumor growth
in vivo, and no apparent toxicity was observed. These stud-
ies demonstrated that alantolactone could selectively ablate
LSCs with little effect on normal hematopoietic cells. To
our knowledge, this is the first report of a eudesmane-type
sesquiterpene lactone with anti-LSCs activity.
Methods
Materials
Cell culture medium reagents, MTT, and DMSO were pur-
chased from Sigma Chemical Company (St. Louis, MA,
USA). Rabbit polyclonal anti-human p65, XIAP, FLIP, Bax,
Bcl-2, PARP, caspase-3, caspase-9, and β-actin antibodies
were purchased from Cell Signaling Technology (Beverly,
MA, USA). Fetal bovine serum (FBS) was purchased from
Gibco (NY, USA). Cell lysis buffer was purchased from
Beyotime Institute of Biotechnology (Beijing, China).
AnnexinV-FITC and PI apoptosis detection kit was pur-
chased from BD (BD, USA). Human CD34-APC, CD38-
PE.cy7, CD33-APC, CD19-PE, CD235a-FITC, and CD3-
APC were purchased from BD (BD, USA). ECL-Plus Kit
was purchased from Thermo Scientific (Rockford, USA).
The isolation of alantolactone and synthesis of DMA-
alantolactone
The air-dried roots of Inula helenium L. (15.0 kg) were
percolated with EtOH (3 × 25 L) at room temperature.
The combined extracts were concentrated under re-
duced pressure. The resulting residue was partitioned
into H2O and extracted with EtOAc. The EtOAc fraction
was subjected to silica gel column chromatography (pet-
roleum ether–EtOAc from 98:2 to 1:1, v/v) to give crude
alantolactone. The crude residue was subjected to re-
peated CC over silica gel (petroleum ether–EtOAc, 10:1,
v/v) and repeated column chromatography over Sepha-
dex LH-20 (MeOH) to afford alantolactone (52 mg).
A mixture of Me2NH·HCl(263 mg, 3.2 mmol), K2CO3
(892 mg, 6.5 mmol), and CH2Cl2 (12 mL) was stirred at
room temperature until Me2NH·HCl was dissolved. The
solid in the mixture was filtered off, and the resulting solu-
tion was treated with alantolactone (50 mg, 0.22 mmol).
The reaction mixture was stirred at room temperature for
3 h. The reaction mixture was concentrated under re-
duced pressure, and the residue was dissolved in CH2Cl2,
and then the solution was washed with water. The organic
layer was dried over anhydrous Na2SO4, concentrated
under reduced pressure to give white solid (50.4 mg,
0.18 mmol). The solid, fumaric acid (21 mg, 0.18 mmol),
and MeOH was stirred for 2 h. The mixture was concen-
trated to afford white product (71.4 mg). The yield of the
two steps is 81.4 %. 1H NMR (400 MHz, D2O) δ 6.59 (s,
2H), 5.05 (d, J = 2.5 Hz, 1H), 4.94 (s, 1H), 3.55 (td, J = 8.5,
5.8 Hz, 1H), 3.45–3.32 (m, 2H), 3.27 (dd, J = 9.8, 6.8 Hz,
1H), 2.89 (s, 6H), 2.46–2.35 (m, 1H), 2.03 (dd, J = 15.2,
3.1 Hz, 1H), 1.74 (dd, J = 26.7, 13.3 Hz, 1H), 1.58–1.24 (m,
6H), 1.08 (s, 3H), 1.01 (d, J = 7.6 Hz, 3H); 13C NMR
(100 MHz, D2O) δ 178.8, 171.0, 153.8, 134. 6, 112.5, 79.9,
54.3, 44.5, 42.4, 41.55, 41.3, 38.2, 37.4, 32.5, 32.3, 28.1,
22.0, 16.2; HRMS (ESI) calcd for C17H27O2 [M+H]
+
278.212, found 278.2120 (Additional file 1).
Cell culture
Human leukemia cell lines THP-1, KG1a, HL60, K562,
HL60/ADR, and K562/A02 were cultured in 1640
medium containing with 10 % fetal bovine serum at 37 °
C, 5 % CO2 incubator. Mononuclear cells isolated from
the primary human AML samples using Ficoll-Paque
density gradient separation were cultured in serum-free
IMDM medium for 1 h, and then the cells were cultured
with different concentrations of alantolactone.
Cytotoxicity assay
MTT assay was usually used to measure cell viability
and cytotoxicity of anti-cancer drugs. Briefly, leukemia
cells were seeded in 96-well plates (1 × 104 cells/well).
Then, cells were treated with various concentrations of
alantolactone and control group was treated by DMSO.
After 72-h treatment of alantolactone, 20 μL MTT solu-
tion (5 mg/mL) was added to each well and then incu-
bated in 37 °C, 5 % CO2 incubator for additional 4 h.
After being centrifuged by 1500 rpm for 15 min, all
supernatant were removed and 100 μL DMSO was
added to each well to dissolve the formazan crystal. Ab-
sorbance was measured at 570 nm using a micro-plate
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reader (synergy H4, BioTek, USA). Then the IC50 value
was analyzed by GraphPad Prism 5 project.
Apoptosis assay
Apoptosis was assayed by flow cytometry, and apoptosis
status of KG1a cells was stained with APC-Annexin V
and 7-aminoactinomycin (7-AAD) with Apoptosis Assay
kit (BD, USA) according to the manufacturer’s protocol.
Briefly, 1 × 105 KG1a cells or 1 × 106 primary AML
mononuclear cells were seeded in six-well plate. After 1-
h incubation, cells were treated by different concentra-
tion of alantolactone for 24 or 18 h, and then cells were
harvested and washed by cold PBS for three times. Cells
were re-suspended with 1× binding buffer, and 5 μL
APC-Annexin V and 5 μL 7-AAD were added to stain
cells. After incubation 15 min in the dark, cells were an-
alyzed by flow cytometry.
Differentiation assay
AML mononuclear cells were obtained from AML sam-
ples by density gradient centrifugation. CD34+ AML cells
were enriched by magnetic-activated cell sorting CD34
progenitor kit (Miltenyi Biotech, Auburn, CA, USA). After
enriched, CD34+ cells were cultured in IMDM supple-
mented with 10 % fetal calf serum. Cytokines were added
at the concentration of 100 ng/mL for rhSCF, 100 ng/mL
for rhFlt3, and 100 ng/mL for rhTPO. Then cells were
treated with various concentrations of alantolactone. After
3 days, cells were collected and stained with CD19-PE,
CD33-APC, CD3-APC, and CD235a-FITC for 30 min, re-
spectively. The cells were re-suspended and analyzed by
flow cytometry.
LSCs apoptosis assay in AML samples
The effect of alantolactone on LSC cells was analyzed by
flow cytometry. The primary AML mononuclear cells
were obtained from AML patients. The mononuclear
cells which was isolated from primary AML patients
were seeded in 24-well plates (1 × 106 cells/well), and
medium volume was 1 mL. Then, cells were treated with
various concentrations of alantolactone. After 18-h treat-
ment, the cells were re-suspended with PBS and stained
with CD34-APC and CD38-PE.cy7 for 30 min, and then
the cells were re-suspended with 1× binding buffer
which contained 5 μL Annexin-V-FITC and 5 μL PI.
Samples were analyzed by flow cytometry in 1 h.
Clonogenic assay
Mononuclear cells were cultured in serum-free IMDM
medium for 18 h in the presence or absence of alanto-
lactone or Ara-C. Cells were plated at 200,000 cells/mL
in MethoCult H4434 (stem cell). Cells were cultured for
14 days, and the number of colonies formed was
counted under microscope.
Acute toxicity assay in Kunming mice
Five 5-week-old Kunming mice (Chinese Academy of
Sciences, Shanghai, China) were dosed orally with
DMA-alantolactone at a single dose of 500 mg/kg. After
administration, the mice were observed for their behav-
ior and appetite. The body weight of the mice was
weighed every day.
Nude mice tumor growth inhibition assay
KG1a cells were collected and washed with PBS once.
Then KG1a cells (1 × 107 cells/0.1 mL PBS) were
injected into 5-week-old female BALB/c nude mice
(Chinese Academy of Sciences, Shanghai, China). After
20 days, tumor volume reached to 500 mm3, and tumor
was cut to the same volume (0.5 mm3). And then small
tumor pieces were implanted into mice. Tumor volumes
and weights were measured every 3 days with an auto-
matic vernier caliper. When tumor volume reached to
100 mm3, DMA-alantolactone was administrated by oral
every 3 days with 100 mg/kg. Mice were sacrificed after
30 days. Tumor growth curves and growth inhibition
rates were calculated. Five mice were used for each ex-
perimental group and control group. Animal assay was
performed according to national and international
guidelines, and mice were cultured in the Animal Ethics
Committee of the Institute of Hematology & Hospital of
Blood Diseases, Chinese Academy of Medical Sciences &
Peking Union Medical College.
Western blot assay
KG1a, HL60, and primary CD34+ AML cells were har-
vested after treatment by different concentrations of
alantolactone for 12 h, re-suspended in cell lysis buffer
RIPA (Beyotime, China) with 1 % phenylmethanesulfonyl
fluoride (PMSF) and then incubated on ice for 30 min.
Cell supernatants were mixed with loading buffer and
boiled for 10 min at 100 °C, and protein samples were
separated by SDS-PAGE in a 12 % gel. After electro-
phoresis, proteins were transferred into nitrocellulose
(NC) membrane and blocked with 5 % non-fat milk
powder in PBST buffer (PBS with 0.05 % Tween-20) for
1 h at room temperature. The membrane was incubated
with diluted primary antibody at 4 °C overnight. The
membrane was washed with PBST for three times and
then incubated with HRP-conjugated secondary anti-
body for 2 h at room temperature. Finally, proteins were
assayed by an ECL-Plus Kit.
Statistical analysis
Results were repeated more than three independent ex-
periments and each experiment was done in triplicate.
Student’s t test was performed with GraphPad Prism5
software to analyze the significance level, and the P value
of less than 0.05 was considered to be statistically
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significant. Error bars denoted the standard deviation
(SD), unless stated otherwise.
Results
Alantolactone inhibited the proliferation of different
leukemia cells in vitro
Initial studies were performed to examine the cytotox-
icity of alantolactone in different leukemia cell lines in
vitro, including human leukemia cell lines HL60, K562,
their multidrug-resistant counterparts HL60/ADR,
K562/A02, respectively, and a human AML cell line,
THP-1 (Fig. 1, Table 1). All leukemia cells were cultured
with alantolactone for 72 h. Alantolactone showed sig-
nificant inhibitory effect on the HL60 and K562 cells
with IC50 values of 3.26 and 2.75 μM, respectively. Fur-
thermore, the activities against drug-resistant cell lines
HL60/ADR (IC50 = 3.28 μM) and K562/A02 = 2.73 μM)
were comparable to their counterparts the sensitive cell
lines HL60 and K562, while ADR, a clinically used drug,
exhibited 205- to 59-fold IC50 values for the drug-
resistant cell lines HL60/ADR and K562/A02 comparing
to those of the sensitive cell lines HL60 and K562, re-
spectively. Alantolactone was active against human AML
cell line THP-1 with IC50 value of 2.17 μM. Alantolac-
tone demonstrated anti-cancer activity with a dose-
dependent manner in different leukemia cell lines.
Previous studies indicated that KG1a cell line is a type of
AML progenitor cell line which showed high multidrug re-
sistance and self-renewal potential. Furthermore, KG1a
cells had a large portion of cells bearing a CD34+CD38–
immunophenotype which was considered to be characteris-
tic of LSCs. Therefore, KG1a was considered to be a LSCs-
like cell line and an ideal cell line for preliminary screening
of potential anti-AML stem cell agents [28–30]. We further
examined the potency of alantolactone against KG1a. It is
noteworthy that alantolactone showed high growth inhib-
ition to KG1a (IC50 = 2.75 μM), which is comparable to that
against HL60 and HL60/ADR.
Fig. 1 Cytotoxicity of alantolactone against different leukemia cell lines. Cytotoxicity was assayed by MTT. HL60, HL60/ADR, KG1a, K562, K562/A02,
and THP-1 cells were treated with a range dose of alantolactone (1.25, 2.5, 5, 10, 20, and 50 μM) for 72 h, respectively. Numerical analysis data
represented mean ± SD based on three independent experiments
Table 1 Inhibitory effect of alantolactone on different leukemia
cell lines
Cell lines IC50 (μM)
a
Alantolactone ADR
K562 2.75 ± 0.64 0.15 ± 0.08
K562/A02 2.73 ± 0.83 8.94 ± 3.79
HL60 3.26 ± 0.88 0.027 ± 0.022
HL60/ADR 3.28 ± 0.80 5.54 ± 1.21
THP-1 2.17 ± 0.72 0.06 ± 0.038
KG1a 2.75 ± 0.65 0.62 ± 0.15
Normal cell 26.37 ± 4.04 N/A
ADR adriamycin, used as a positive control
aAll values are the mean of three independent experiments
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In view of the high activity against AML cells, alantolac-
tone was further studied to evaluate its selectivity against
AML cells over normal cells. Normal hematopoietic cells
were collected from healthy donors. The result indicated
that alantolactone did not show significant effect on the
viability of normal cells with IC50 value of 26.37 μM
(Table 1). The selectivity index for KG1a and normal cells
was 9.6, which suggested that alantolactone could select-
ively eliminate AML cells (IC50 = 2.75 μM for KG1a) with
relatively low toxicity against normal hematopoietic cells
(IC50 = 26.37 μM).
Alantolactone induced apoptosis and differentiation of
stem-like cells
We examined the population of LSCs in the KG1a cell
line, which was reported to contain 54 % CD34+CD38–
cells [28]. From our result of flow cytometry, the percent-
age of CD34+ cells in KG1a cell line was 99.3 %, and the
percentage of CD34+CD38– was 37.4 % (Fig. 2a), confirm-
ing that KG1a represented a AML stem-like cell line. In
differentiation assay, alantolactone resulted in a significant
increment in the frequency of lymphocyte cell (CD19), T
cell (CD3), and erythroid cell (CD235a) and a significant
decrease in the frequency of myeloid cell (CD33) (Fig. 2b).
Alantolactone exerted a dose-dependent cytotoxic effect
on total primary AML cells from AML specimens (Fig. 2c).
Furthermore, apoptosis was determined by APC Annexin
V and 7-AAD staining and was assessed by flow cytome-
try. Alantolactone induced apoptosis in KG1a cells with a
dose-dependent manner. After culturing with alantolac-
tone for 24 h, the apoptotic percentage of KG1a was 10.9
± 0.35 % (2.5 μM), 20.8 ± 3.12 % (5 μM), and 36.0 ± 1.56 %
(10 μM) comparing with negative control 8.27 ± 0.92 %
(DMSO) in KG1a cells (Fig. 2d).
Alantolactone specifically induced apoptosis of primary
AML stem and progenitor cells while sparing normal
hematopoietic stem and progenitor cells
In previous study, alantolactone showed potent anti-
cancer activity [25–27]; however, there was no study on
the effect of alantolactone on LSCs. To investigate the
effects of alantolactone on selectively targeting LSCs, we
Fig. 2 Alantolactone induced the apoptosis and differentiation of leukemia stem-like cell line KG1a and primary AML cells. a The expression of CD34
+CD38– on the surface of KG1a cells by flow cytometry. The χ axis represented CD34-APC, and the Y axis represented CD38-AF488. b Alantolactone
induced the differentiation of leukemia stem cells after 3 days treatment. c Alantolactone induced apoptosis of primary AML cells with a dose-dependent
manner after the treatment of alantolactone for 18 h. Each point represents an AML specimen. d Alantolactone induced apoptosis with a dose-dependent
manner in KG1a cells with the treatment of alantolactone for 24 h. Analysis results represented mean ± SD based on three independent experiments,
**P< 0.01, ***P< 0.0001
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initially studied the effects of alantolactone on primary
leukemia specimens during suspension culture. The re-
sult is described in Table 2. The viability of the cells,
bearing a CD34+CD38– immunophenotype which were
considered to be characteristic of LSCs, was determined
after treatment with 2.5, 5, and 10 μM alantolactone for
18 h. At a concentration of 2.5 μM, three of the speci-
mens, AML9, AML12, and AML13, showed excellent
response with very low viability (0, 6.6, and 6.2 % viable
CD34+CD38– cells, respectively). The viability of most of
specimens was greatly reduced by increasing concentra-
tion of alantolactone to 10 μM, with the exception of
AML2, AML6, AML14, AML15, and AML18 with
>25 % viable CD34+CD38– cells. Alantolactone induced
apoptosis of primary AML CD34+CD38– cells with a
dose-dependent manner (Fig. 3a, e). Moreover, the per-
centage of CD34+CD38– cells in total viable cells was
also decreased (Fig. 3b).
For analysis of the effect of alantolactone selectively
targeting LSCs, we analyzed and compared the viability
of both the total and CD34+CD38– cells. As shown in
Fig. 3c, alantolactone showed high toxicity to both of the
total and CD34+CD38– cells. It is notable that CD34
+CD38– cells were more sensitive to alantolactone than
the total primary cells.
To further evaluate the potency of alantolactone, we
also studied the efficacy of the standard chemotherapy
drug Ara-C on CD34+CD38– cells from AML specimen
for comparison. Ara-C demonstrated very little toxicity
to total primary AML cells, especially to CD34+CD38–
cells with almost no efficacy (Fig. 3d, f ). Both of normal
HSCs and LSCs are with characteristic of bearing CD34
+CD38– immunophenotype. Therefore, we further evalu-
ated the cytotoxicity of alantolactone against normal
hematopoietic stem cells from the umbilical cord. As
shown in Fig. 3g, normal CD34+CD38– cells showed
relatively less apoptotic response to alantolactone treat-
ment comparing with the response to leukemia stem
cells at 10 μM. Taken together, these results demon-
strated that alantolactone had specific toxicity against
LSCs while relatively less toxicity to normal HSCs.
Alantolactone suppressed AML but not normal colony
formation
Colony formation assay was conducted to determine the
effect of alantolactone on the potential of primitive cells.
After treatment with alantolactone, the number of
colony-forming units (CFUs) of AML stem/progenitor
cells significantly decreased comparing with the control
group in a dose-dependent manner (Fig. 4a, b). More-
over, CFUs of normal hematopoietic cells from the um-
bilical cord showed a little effect. In contrast, normal
colony formation was greatly reduced at a concentration
of 5 μM Ara-C (Fig. 4c, d). Comparing with Ara-C, alan-
tolactone presented significant selectivity on colony for-
mation of primary AML cells. The result indicated that
alantolactone treatment affected AML but not normal
colony formation.
Alantolactone effectively inhibited tumor growth in vivo
Taking into account that alantolactone showed signifi-
cant cytotoxicity against AML cells in vitro, we planned
to evaluate alantolactone for its anti-AML activity in
vivo. However, alantolactone showed low solubility in
water. Therefore, alantolactone was converted to its pro-
drug, DMA-alantolactone (Fig. 5a). Firstly, we evaluated
the acute toxicity of DMA-alantolactone in normal Kun-
ming mice. As shown in Fig. 5b, the body weight of mice
was not apparently changed after a single oral adminis-
tration of 500 mg/kg. All mice remained alive, and no
significant side effects were observed. When tumor vol-
umes reached to 100 mm3, DMA-alantolactone was ad-
ministrated and data presented that tumor sizes were
significantly suppressed with comparing to control
group (Fig. 5c). Moreover, weight of the mice did not
change obviously. The result demonstrated that DMA-
alantolactone could greatly inhibit tumor growth in vivo.
Table 2 Viability of primary AML cells treated with
alantolactone
AML
specimens
Viability of CD34+CD38− (%)a
2.5 μM 5 μM 10 μM
AML1 67.9 10.0 2.1
AML2 74.5 62.1 43.7
AML3 75.9 19.6 1.5
AML4 17.9 10.4 8.9
AML5 58.8 46.3 24.7
AML6 85.4 70.6 66.9
AML7 40.3 9.6 4.6
AML8 86.1 29.8 3.2
AML9 0.0 0.0 0.0
AML10 19.6 15.0 7.2
AML11 53.3 6.4 5.0
AML12 6.6 3.2 2.1
AML13 6.2 2.0 0.0
AML14 35.4 28.4 25.5
AML15 91.7 31.6 26.6
AML16 76.3 35.3 6.0
AML17 37.5 28.9 8.9
AML18 85.5 70.5 67.0
All values were carried out as triplicate
aThe percentage of viability was normalized to untreated control
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Alantolactone induced apoptosis by the suppression of
NF-kB and its downstream target proteins
For exploring the way of alantolactone inducing apoptosis,
we assayed the status of apoptosis by Western blot ana-
lysis of Bcl-2, Bax, caspase-3, caspase-9, p65, XIAP, FLIP,
and PARP in primary CD34+, HL60, and KG1a cells. Bcl-2
family played an important role in the regulation of apop-
tosis, and the expression level of Bcl-2 and Bax proteins
were usually assayed for characteristic of apoptosis. After
24-h treatment of alantolactone, the expression of Bcl-2,
the inhibitors of apoptosis, was significantly reduced and
the expression of Bax, the pro-apoptotic protein, was in-
creased comparing with control group (Fig. 6). Caspase-3,
caspase-9, and PARP were major factors in cell death cas-
cade. We examined the effects of alantolactone on the ac-
tivation of caspase-3, caspase-9, and PARP. Cleavages of
caspase-3, caspase-9, and PARP were increased with treat-
ment of alantolactone. The expression of p65 which
played important roles in NF-kB signal pathway decreased
significantly. Meanwhile, the levels of XIAP and FLIP, the
downstream target proteins of NF-kB, were reduced sim-
ultaneously after the treatment of alantolactone.
Fig. 3 Alantolactone selectively induced apoptosis of LSCs in primary AML cells. a Alantolactone induced the apoptosis of CD34+CD38– cells with
a dose-dependent manner in primary AML cells from AML specimens after treatment of alantolactone for 18 h. Each point represents an AML
specimen. b Alantolactone reduced the percentage of CD34+CD38– cells with a dose-dependent manner in primary AML cells after the treatment
of alantolactone for 18 h. Each point represents an AML specimen. c Alantolactone selectively induced apoptosis of CD34+CD38– cells comparing
with total cells in primary AML cells after the treatment of alantolactone for 18 h by flow cytometry. d Ara-C showed negligible cytotoxicity to
CD34+CD38– and total cells in primary AML cells at the concentrations of 5 and 10 μM. e Alantolactone induced apoptosis of CD34+CD38– cells
in primary AML cells by flow cytometry at the concentrations of 2.5, 5, and 10 μM. f Ara-C showed almost no effect on inducing apoptosis of
CD34+CD38– cells in primary AML cells at the concentrations of 5 and 10 μM. g Alantolactone treatment demonstrated significantly less effect
on inducing apoptosis of CD34+CD38– cells in normal hematopoietic cells comparing to that in primary AML cells at a concentration of
10 μM. *P < 0.05, **P < 0.01, ***P < 0.0001
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Discussion
AML is one of the most common forms of malignant
myeloid leukemia in adults. There are several strategies in
clinical treatments for younger adults. However, it remains
a challenge to increase the survival and cure rates for pa-
tients who are older than 70 years [31]. Drug resistance
and recurrence are the main obstacles for treatment of
AML. Finding new anti-AML agents or targeting AML
therapies is presently an active area for clinical trials [2]. A
small population of AML cells with self-renewal function
is considered to be LSCs. It has been reported that LSCs
which bear the CD34+CD38– immunophenotype play the
major role for initiation of leukemia, drug resistance, and
recurrence of leukemia, and are related to minimal re-
sidual disease (MRD) [32, 33]. Selectively targeting LSCs
is postulated to prevent tumor relapse and drug resistance
without damage of the normal hematopoietic stem cells.
Alantolactone, a sesquiterpene lactone isolated from I.
helenium L., has been studied as a potential anticancer
agent in several different cancer lines [34–36]. Alanto-
lactone could reduce P-glycoprotein expression in drug
resistant cell line K562/adriamycin for drug resistance
treatment [37]. It has been reported to obtain alantolac-
tone by separating from Chinese herbs [38]. Herein, our
Fig. 4 Alantolactone suppressed primary AML but not normal colony formation after 14 days in MethoCult H4434. a Alantolactone dramatically
reduced the number of CFUs in primary AML cells from eight AML specimens with a dose-dependent manner. b The representative microscopy
images of CFUs in primary AML cells were shown. c Alantolactone showed little effect on the CFUs in normal hematopoietic cells and Ara-C
treatment led to notable reduction of colonies from normal donors. d The representative microscopy images of CFUs in normal hematopoietic
cells were shown. *P < 0.05, **P < 0.01, ***P < 0.0001
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research first reveals that alantolactone can selectively
target LSCs.
Alantolactone exhibited comparable cytotoxicity to
drug-resistant cell lines K562/A02, HL60/ADR with drug
sensitive cell lines K562 and HL60 (Fig. 1, Table 1). It
was reported that LSCs showed the character of multi-
drug resistance. The cell line KG1a, which exhibited
high P-glycoprotein-mediated drug efflux capacity and a
high level of DNR resistance, showed a strong response
to alantolactone treatment. The previous work [28] and
the present study indicated that KG1a, bearing a high
level of CD34+ and CD34+CD38–, was a stem-like cell
line (Fig. 2). We hypothesized that such agents that sup-
press drug-resistant cells would lead to a positive re-
sponse to cancer stem-like cells. Alantolactone exerted
anti-AML activity by inducing apoptosis of AML cells.
We assayed the apoptosis of primary AML cells from
clinical specimens. Among 18 primary AML samples,
Fig. 5 DMA-alantolactone inhibited tumor growth effectively in vivo. a Synthesis of the pro-drug of alantolactone, i.e., DMA-alantolactone. b The
body weight of the mice after the oral administration of alantolactone at a dose of 500 mg/kg. c KG1a cells were injected into 5-week-old female
BALB/c nude mice. After 20 days, tumor was cut to the same volume (0.5 mm3). The small tumor pieces were implanted into mice. When tumor
volume reached to 100 mm3, DMA-alantolactone was administrated by oral every 3 days with 100 mg/kg. Mice were sacrificed after 30 days. *P
< 0.05, **P < 0.01, ***P < 0.0001
Fig. 6 Alantolactone induced apoptosis by the suppression of NF-kB and its downstream target proteins. The expression of p65, XIAP, FLIP, Bcl-2,
Bax, and the cleavage of PARP, caspase-3, caspase-9 was detected by western blot assay after the treatment of alantolactone for 12 h in primary
CD34+ cells, HL60, and KG1a cells
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the viability of CD34+CD38– cells from most of
specimens was greatly reduced with treatment of alanto-
lactone at a concentration of 10 μM (Table 2). Further-
more, alantolactone was more toxic to CD34+CD38–
cells than total primary leukemia cells. In contrast, the
traditional chemotherapy drug Ara-C exhibited little
apoptosis when tested against total primary leukemia
cells abf CD34+CD38- cells at concentrations of 5 and
10 μM (Fig. 3). It is noteworthy that CD34+CD38– cells
of normal hematopoietic cells from the umbilical cord
were almost unaffected with treatment of alantolactone
at concentrations of 2.5 and 5 μM (Fig. 3). To further
confirm the inhibitory effect of alantolactone on colony
formation for primary AML cells, a colony formation
assay was performed. Alantolactone significantly inhib-
ited the number of CFUs in AML cells at a concentra-
tion of 2.5 μM, while the number of CFUs was little
affected in normal hematopoietic cells at the same con-
centration (2.5 μM). In contrast, Ara-C strongly inhib-
ited the number of CFUs in normal hematopoietic cells
at the concentration of 5 μM (Fig. 4).
The above-mentioned experiments revealed that
alantolactone exhibited significant anti-AML activity
in vitro, which promted us to carry out in vivo
experiments with the KG1a, an AML stem-like cell
line. The prodrug of alantolactone, i.e., DMA-
alantolactone, was evaluated in vivo (Fig. 5a). Acute
toxicity assay indicated that DMA-alantolactone had
little toxicity to normal mice with a single dose of
500 mg/kg (Fig. 5b). Meanwhile, DMA-alantolactone
greatly inhibited the tumor size after the treatment
comparing with control group. DMA-alantolactone
could suppress tumor growth in vivo (Fig. 5c).
The expression of NF-kB in normal hematopoietic
stem cells was low, while it was overexpressed signifi-
cantly in leukemia stem cells [39]. Therefore, the expres-
sion and activity inhibition of NF-kB could be a
potential therapeutic target for targeting leukemia stem
cell. The expression of NF-kB and NF-kB-regulated pro-
teins such as p65, Bcl-2, XIAP, and FLIP played import-
ant roles in cell apoptosis. It was reported that
parthenolide and micheliolide, with chemically reactive
alpha-beta unsaturated lactone moiety, were able to co-
valently bind to proteins via the Michael acceptor and
eliminate leukemia stem cell by inhibiting the activity of
NF-kB [17, 19, 39]. We speculated that compounds with
alpha-beta unsaturated lactone moiety might share some
common protein targets. Alantolactone also contained
the moiety of alpha-beta unsaturated lactone, which
prompted us to suppose that alantolactone would target
AML stem cells by inhibiting the activity of NF-kB. The
primary studies for mechanism of the anti-AML stem
cell activity of alantolactone were performed. After the
treatment of alantolactone, the expression of Bcl-2, p65,
XIAP, and FLIP reduced and the expression of Bax in-
creased obviously comparing with control group. In-
creasing cleavages of PARP, caspase-3, and caspase-9
were observed with the treatment of alantolactone
(Fig. 6). These results indicated that alantolactone in-
duced the apoptosis of AML stem cells mainly by the
suppression of NF-kB and its downstream target
proteins.
It is worth to note that the yield of alantolactone in I.
helenium L. was extremely low, which would hamper
the development of alantolactone as an anti-AML agent.
We identified that isoalantolactone is the major con-
stituent of I. helenium L. (0.6 %), and the structure of
isoalantolactone is similar to alantolactone. Therefore,
we proposed to convert isoalantolactone to alantolactone
to circumvent the hurdle, and the study is ongoing in
our lab.
Conclusions
In summary, alantolactone, a prominent naturally occur-
ring eudesmane-type sesquiterpene lactone, was firstly
demonstrated to be a potential agent that can selectively
target LSCs with negligible toxicity towards normal cells.
Alantolactone induced apoptosis of AML stem cells by
the suppression of NF-kB and its downstream target
proteins. DMA-alantolactone, a water-soluble prodrug of
alantolactone, was shown to inhibit tumor growth in
vivo. Based on these results, we propose that alantolac-
tone might be used as a potential LSC-targeted agent,
and eudesmane-type sesquiterpene lactones represent a
new scaffold for drug discovery of novel anti-LSCs
agents.
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